Clinical trials: Enterovirus
Enterovirus Infections
A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old
The objectives of this study are to evaluate the immune response and safety profiles of two injections of EV71 vaccine administrated with or without adjuvant AlPO4 at 0.5-μg, 1-μg, 2-μg and 5-μg dose (if required) in children…
- Trial name
- NCT02777411
- Testing
- EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose), EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose), EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)
- Where
- 4 sites in Taiwan
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Enimmune Corporation
Poliomyelitis
Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)
The study aimed to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine in infants aged two months (60~89 days).
- Trial name
- NCT07297186
- Testing
- sIPV, wIPV
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Hand, Foot and Mouth Disease (HFMD)
The Phase IVb of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Children
Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae.
- Trial name
- NCT03001986
- Testing
- inactivated EV71 vaccine (KMB-17 cells)
- Where
- China
- Volunteers
- 40,724 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Hepatitis A
Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)
This safety surveillance study is being conducted in accordance with Korea Food and Drug Administration (KFDA) "Basic standard for reexamination of new drug".
- Trial name
- NCT01838070
- Where
- South Korea
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B, Polio
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule
To demonstrate that the immune response to hepatitis B antigen of the DTaP-IPV-Hep B-PRP~T is non-inferior to that of the association of PENTAXIM™ and ENGERIX B® one month after a three dose (2-3-4 month) primary series.
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00315055
- Testing
- DTaP-IPV-HB-PRP~T vaccine, DTaP-IPV//PRP~T combined, Hepatitis B vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hand, Foot and Mouth Disease
Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine
The main purpose of this study is to evaluate the immunogenicity and safety of inactivated enterovirus type 71 vaccine combined with recombinant hepatitis B vaccine or Group a meningococcal polysaccharide vaccine.
- Trial name
- NCT06209398
- Testing
- Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell ), Recombinant Hepatitis B Vaccine, Group A meningococcal polysaccharide vaccine
- Where
- China
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Hepatitis A, Hepatitis B
Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult
This study will evaluate the persistence of the immune response to HAV (Hepatitis A Virus) antigens and HBs (Hepatitis B surface) antigens in healthy adults previously vaccinated with GlaxoSmithKline (GSK) Biologicals' Twinrix…
- Trial name
- NCT01000324
- Testing
- Blood sampling, Engerix-B, Havrix
- Where
- Belgium
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis
Clinical Trial of Novel OPV2 Vaccine
Though OPV is safe and effective, it can mutate and reacquire neurovirulence in rare circumstances. This can result in vaccine-associated paralytic polio and circulating vaccine-derived polioviruses.
- Trial name
- NCT04693286
- Testing
- novel oral polio type 2 vaccine (nOPV2)
- Where
- Bangladesh
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Acellular Pertussis, Diphtheria
Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine
The purpose of this booster study is to evaluate, in subjects primed in the primary study 106786, the persistence, at the time of the booster vaccination, of antibodies elicited by the different formulation of DTPa-HBV-IPV/ Hib…
- Conditions
- Acellular Pertussis, Diphtheria, Poliomyelitis, Haemophilus Influenzae Type b
- Trial name
- NCT00627458
- Testing
- Infanrix Hexa
- Where
- 6 sites in Finland
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Poliomyelitis
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults
This study will evaluate the persistence of immune response against diphtheria, tetanus, pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also assess the immunogenicity and safety of another…
- Conditions
- Acellular Pertussis, Poliomyelitis, Diphtheria, Tetanus
- Trial name
- NCT01323959
- Testing
- BoostrixTM Polio
- Where
- 15 sites in France, Germany
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Polio
Evaluation of Integrating MIYCN Interventions in Existing CGPP of PCI
The study has two arms; both experimental and control areas will receive standard interventions given under polio eradication program of PCI.
- Trial name
- NCT03368885
- Testing
- Maternal dietary diversity, Diet diversity in complementary feeding, Exclusive Breast Feeding
- Where
- India
- Volunteers
- 2,590 people, healthy volunteers welcome
- Sponsor
- FHI 360
Measles, Mumps
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
The present study will explore the immunogenicity of AVAXIM™ 80U-Pediatric in 12-13 months Turkish children and check if the administration of the MMR trivalent vaccine on the same day but at different site will interfere on…
- Conditions
- Measles, Mumps, Rubella, Hepatitis A
- Trial name
- NCT00313950
- Testing
- Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella, Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants
The purpose of this phase III study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in 2-month-old infants.
- Trial name
- NCT03526978
- Testing
- Investigational sIPV, Control IPV
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Diphtheria, Tetanus
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
Objectives: To present the rates of adverse reactions after a dose of DAPTACEL® vaccine administered to children 4 to 6 years of age who have previously received four doses of PENTACEL™ vaccine.
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT00802867
- Testing
- Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
- Where
- 19 sites in United States
- Volunteers
- 989 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis, Polio
Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV
This study is intended to support the registration of IMOVAX Polio in China. The primary objective of this Pase III trial is to compare IMOVAX Polio to the current Chinese standard of care (OPV) that is administered following a…
- Trial name
- NCT00348387
- Testing
- Poliomyelitis Vaccine inactivated, Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Enterovirus 71 Vaccine
Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old
This phase IV clinical study evaluates the safety of enterovirus 71 vaccine in children aged 6-35 months old by the method of both passive and active surveillance.
- Trial name
- NCT02806531
- Testing
- two doses enterovirus 71 vaccine
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Beijing Chaoyang District Centre for Disease Control and Prevention
Hepatitis A
Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine
The primary purpose of the original study was to assess whether the protection afforded by the paediatric dose of Epaxal vaccine against hepatitis A was not inferior to the protection afforded by the standard dose of Epaxal.
- Trial name
- NCT01405677
- Testing
- Epaxal 0.25 mL, Epaxal 0.5 mL, Havrix Junior 0.5 mL
- Where
- 2 sites in Belgium
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Poliomyelitis
The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)
Based on pre-clinical trial and phase 1 clinical data and principle of GCP, the objective of phase Ⅱ clinical trial is to evaluate safety and immunogenicity of Inactivated Poliomyelitis Vaccine made from Sabin Strains(Sabin IPV).
- Trial name
- Sabin IPV (NCT01056705)
- Testing
- Inactivated Poliomyelitis Vaccine (Sabin strains), Oral Poliomyelitis Vaccine, Inactivated Poliomyelitis Vaccine (Salk strains).
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Diphtheria, Tetanus
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
The purpose of this study is to describe the immunogenicity and safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T fully liquid combined hexavalent vaccine (Hexaxim®) administered at 2, 3, and 4 months of age and at 16 to 17 months…
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT02428491
- Testing
- Hexaxim®
- Where
- Vietnam
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hand, Foot and Mouth Disease
Safety Observation of Enterovirus 71 Inactivated Vaccine (Vero Cell) Combined Immunization in Shanghai
This study is an open clinical trial of the EV71 vaccine (Vero cell), Inactivated manufactured by Sinovac Research \& Development Co.,Ltd.The purpose of this study is to evaluate the safety of EV71 vaccine (Vero cell)…
- Trial name
- NCT05166044
- Testing
- EV71 Inactivated Vaccine
- Where
- 6 sites in China
- Volunteers
- 12,500 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd